Mandate

Vinge has advised EQT in connection with the combination with Baring Private Equity Asia

Vinge has advised EQT in connection with the combination with Baring Private Equity Asia, a leading private markets investment firm in Asia with EUR 17.7bn of assets under management. The total consideration amounts to EUR 6.8bn.

Through the transaction, EQT will acquire 100 percent of the BPEA management company, the BPEA general partner entities which control the BPEA funds, and the right to carried interest in selected existing funds. The total consideration amounts to EUR 6.8bn, of which approximately EUR 5.3bn to be paid through the issue of 191.2 million new EQT ordinary shares (corresponding to a dilution of approximately 16%), plus EUR 1.5 billion in cash. The transaction is subject to customary closing conditions and the completion is expected to be carried out during the fourth quarter of 2022.

Vinge’s team mainly consists of Sofie Bjärtun, Erik Sjöman, Linnéa Sellström, Joel Magnusson, Lorin Arabi, Pernilla Björklund, Marcus GladerEmma Johansson, Sebastian Örndahl, Jesper Ekman and Adam Löfquist

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026